Best Practices for Preclinical In Vivo Testing of Cancer Nanomedicines.

ABSTRACT: Significant advances have been made in the development of nanoparticles for cancer treatment in recent years. Despite promising results in preclinical animal models, cancer nanomedicines often fail in clinical trials. This failure rate could be reduced by defining stringent criteria for testing and quality control during the design and development stages, and by performing carefully planned preclinical studies in relevant animal models. This article discusses best practices for the evaluation of nanomedicines in murine tumor models. First, a recommended set of experiments to perform is introduced, including discussion of the types of data to collect during these studies. This is followed by an outline of various tumor models and their clinical relevance. Next, different routes of nanoparti

SUBMITTER: Valcourt DM 

PROVIDER: S-EPMC7473451 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature